IMU Biosciences announces oversubscribed financing round
IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank and Meltwind alongside existing investors.
IMU has built the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026 through unrivalled access to patient samples and population wide clinical data. By combining high-fidelity multi-omic analysis with proprietary machine learning analytics, IMU can use a simple blood sample to measure over 100 million immune data points, creating the most detailed immune picture ever assembled at clinical scale.
With its data, the Company is establishing a universal standard for immune profiling which will enable the discovery of new immune mechanisms and identify precision approaches, monitor disease progression and the course of treatment, and predict treatment suitability and efficacy for individual patients.
To date, IMU has raised $60 million (£45 million) and is primed to deliver on its vision to fundamentally change how we understand, diagnose, and treat disease. The proceeds from this latest round will be used to support the Company’s operational expansion and clinical platform, and infrastructure development.
The funding will also be used to advance IMU’s clinical programmes including, its Stem Cell Transplant and Solid Organ Transplant Programmes in addition to MANIFEST, a ground-breaking UK research consortium investigating patient response to cancer immunotherapies.
Dr John Baker, Chief Executive Officer of IMU Biosciences said:
We are delighted to announce IMU’s fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease.
Despite the immune system’s profound importance on all aspects of our health, the system as a whole remains poorly understood – obscured by tools that are fragmented, mechanistic and low-resolution. With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.
Dr Inga Deakin, Partner at Molten Ventures said:
When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we've seen since: a team that executes and a platform that delivers. The immune system sits at the heart of almost every disease; a company that can interrogate it at this resolution has the potential to redefine how we match the right treatment to the right patient at the right time. We're proud to be IMU's largest shareholder and delighted to welcome IQ Capital and the British Business Bank as investors to the round, their support is a further corroboration of what IMU is building. We're excited about what comes next.
Dr Alex Wilson, Partner at IQ Capital said:
We’re thrilled to support IMU on the next step in their journey as a co-lead investor within this latest funding round. With the world’s largest immune dataset and proprietary machine learning analytics, IMU is pioneering research to realise the huge value of health data, creating better insights for clinicians and improved outcomes for patients. We are proud to be a part of the company’s next phase, and are excited to see what the company is able to accomplish as it grows and develops its technology.
Dr Carmine Circelli, Senior Investment Director, Life Sciences at British Business Bank, said:
IMU represents a rare combination of proprietary data scale and deep biological insight. By generating an unprecedented, high-resolution view of the human immune system, the company is creating a foundational platform with the potential to transform how disease is understood and treated. We are excited to support the team as they scale their platform here in the UK and translate this capability into meaningful impact for patients.
